With Isaiah Jackson's re-signing the Pacers now have 15 players on standard contracts. Thomas Bryant and James Johnson Jr. are not among them.

With his relentless energy, Miami Heat forward Keshad Johnson arrived to summer league anxious to take another bite out of his NBA opportunity.

Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Premier Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium investing solutions, free guidance and market analysis on Fool.com, top-rated podcasts, and non-profit The Motley Fool Foundation.

Johnson & Johnson MedTech (NYSE: JNJ) announced that it has a new chief medical & scientific officer for Electrophysiology.

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on

The upcoming report from Johnson & Johnson (JNJ) is expected to reveal quarterly earnings of $2.66 per share, indicating a decline of 5.7% compared to the year-ago period. Analysts forecast revenues of $22.

Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are expected to weigh on performance.